



## Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium

August 28, 2024

ZUG, Switzerland, Aug. 28, 2024 (GLOBE NEWSWIRE) -- [Pharvaris](#) (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for oral presentation and ten abstracts for poster presentation at the upcoming 7th Bradykinin Symposium, to be held from September 5-6, 2024, in Berlin, Germany. Presentation details are as follows:

- **Title:** Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat  
**Presenter:** Jolanta Skarbaliene, Ph.D.  
**Format:** Oral Presentation, Session II  
**Date, time:** Thursday, Sept. 5, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
- **Title:** Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoL  
**Presenter:** Markus Magerl, M.D.  
**Format:** Oral Presentation, Session VII  
**Date, time:** Friday, Sept. 6, 15.05-15.15 CEST (9:05-9:15 a.m. EDT)
- **Title:** Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis  
**Presenter:** Marc A. Riedl, M.D., M.S.  
**Format:** Poster Presentation  
**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- **Title:** Treatment of HAE Attacks with Oral Deucrictibant: RAPIDE-2 Extension Results  
**Presenter:** Emel Aygören-Pürsün, M.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- **Title:** Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results  
**Presenter:** Emel Aygören-Pürsün, M.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- **Title:** Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis  
**Presenter:** Marc A. Riedl, M.D., M.S.  
**Format:** Poster Presentation  
**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- **Title:** Clinical Trials Conformity with AURORA COS: a systematic literature review  
**Presenter:** Remy Petersen, M.D., Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- **Title:** Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant  
**Presenter:** Nieves Crespo, Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- **Title:** The bradykinin challenge model translates across rat, monkey and human  
**Presenter:** Juan Bravo, Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- **Title:** Deucrictibant inhibits carrageenan-induced edema in bradykinin B2 receptor transgenic rat  
**Presenter:** Anne Lesage, Ph.D.  
**Format:** Poster Presentation  
**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)
- **Title:** A novel kinin biomarker assay for characterization of bradykinin-mediated disorders

**Presenter:** Evangelia Pardali, Ph.D.

**Format:** Poster Presentation

**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

- **Title:** A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders

**Presenter:** Evangelia Pardali, Ph.D.

**Format:** Poster Presentation

**Date, time:** Friday, Sept. 6, 15.35-16.15 CEST (9:35-10:15 a.m. EDT)

Upon lift of the embargo, the presentation slides and posters will be available on the Investors section of the Pharvaris website at: <https://ir.pharvaris.com/news-events/events-presentations>.

#### **About Pharvaris**

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all types of HAE effective, well-tolerated, and easy-to-administer alternatives to treat attacks, both in the prophylactic and on-demand setting. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is encouraged to further develop deucricitibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the on-demand treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucricitibant for the prevention of HAE attacks in the coming months. For more information, visit <https://pharvaris.com/>.

Contact Maggie Beller Executive Director, Head of External and Internal Communications [maggie.beller@pharvaris.com](mailto:maggie.beller@pharvaris.com)